No products in the cart.
#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
Click to read this study in The Lancet Oncology.
Tag: advanced breast cancer
Fulvestrant for treatment of estrogen receptor-positive, HER2-negative advanced breast cancer may improve progression free survival using ESR1 mutation as guidance
1. Median progression free survival was longer in the fulvestrant and palbociclib group compared to the aromatase inhibitor plus palbociclib ...
#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
Click to read this study in The Lancet Oncology.
#VisualAbstract: Addition of denosumab to neoadjuvant paclitaxel does not improve complete response rate in breast cancer
Click to read this study in JAMA Oncology.
#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers
Click to read this study in The Lancet Oncology.
Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer
1. Longer progression-free survival was found in patients taking trastuzumab deruxtecan compared to trastuzumab emtansine 2. Adverse events were more ...
Ribociclib in addition to letrozole increases overall survival compared to letrozole alone
1. Overall survival was longer in the group receiving ribociclib with letrozole as compared with the placebo group 2. Severe ...
Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer
1. Ribociclib plus letrozole provides significant overall survival benefit as compared to letrozole alone in patients with advanced breast cancer. ...
#VisualAbstract: Fulvestrant plus cyclin-dependent kinase 4/6 inhibitors improves survival in HR⁺, HER2- metastatic breast cancer
Click to read this study in Lancet Oncology.
#VisualAbstract: Internal mammary node irradiation improves survival for patients with centromedially located node-positive breast cancer
Click to read this study in JAMA Oncology.
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.